Jugan geon-gang gwa jilbyeong · 2025
[Tuberculosis Treatment Outcomes in the Republic of Korea, 2023].
Аннотация на английскомСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kim Jaetae, Seo Soon-Young, Park Young-Joon, Jang You-Jin, Han Heejung, Jang Miri, Kim Hyungjun, Jeon Jin-Hwan, Park Ahyoung, Han Jiyeon, Song Chieeun, Kim Jieun, Kim Jinsun, Lee Hyewon, Choi Seongju, Shim Jiae, Han Sunmi, Park Youngseok, Jeong Hyeran, Kim Hyeongyu, Seo Soonryu, Lee Seung-Eun
Аннотация
OBJECTIVES: To monitor the management of patients with tuberculosis (TB), the Korea Disease Control and Prevention Agency first published the “2023 Tuberculosis Treatment Outcome Report” in 2025. This report analyzes treatment outcomes based on these patients’ clinical and demographic characteristics, serving as a reference for experts and policymakers. This study summarizes the key findings of the 2023 report.
METHODS: Data were obtained from the Korea Tuberculosis Network System, including TB notification reports and case investigation forms. Treatment outcomes were determined by chronologically linking reports from treatment initiation to completion. The final outcome in the most recent notification was used to analyze treatment outcomes.
RESULTS: In 2023, the treatment success rate (TSR) for patients with drug-susceptible TB was 79.3% and decreased with age. The TSR among national health insurance beneficiaries was higher than that of receiving medical aid recipients, and the TSR for new patients was higher than for those previously treated for TB. In 2022, the TSR for patients with multidrug-resistant TB was 72.4% and also decreased with age, primarily due to an increase in deaths.
CONCLUSIONS: Patients more vulnerable to treatment challenges, such as older adults, tend to have lower TSRs. As the number of older patients with TB increases, non-TB-related deaths are also expected to increase, potentially limiting future improvements in TSR. Still, the government will continue to strengthen support policies, such as those promoting medication adherence and treatment continuation, to help vulnerable patients successfully complete their TB treatment.
METHODS: Data were obtained from the Korea Tuberculosis Network System, including TB notification reports and case investigation forms. Treatment outcomes were determined by chronologically linking reports from treatment initiation to completion. The final outcome in the most recent notification was used to analyze treatment outcomes.
RESULTS: In 2023, the treatment success rate (TSR) for patients with drug-susceptible TB was 79.3% and decreased with age. The TSR among national health insurance beneficiaries was higher than that of receiving medical aid recipients, and the TSR for new patients was higher than for those previously treated for TB. In 2022, the TSR for patients with multidrug-resistant TB was 72.4% and also decreased with age, primarily due to an increase in deaths.
CONCLUSIONS: Patients more vulnerable to treatment challenges, such as older adults, tend to have lower TSRs. As the number of older patients with TB increases, non-TB-related deaths are also expected to increase, potentially limiting future improvements in TSR. Still, the government will continue to strengthen support policies, such as those promoting medication adherence and treatment continuation, to help vulnerable patients successfully complete their TB treatment.